Discovery of Potent, Selective, and Direct Acid Sphingomyelinase Inhibitors with Antidepressant Activity

• Published in: Journal of medicinal chemistry Vol. 63; no. 3; pp. 961 - 974
• Main Authors: Yang, Kan, Yu, Jinying, Nong, Keyi, Wang, Youzhi, Niu, Ao, Chen, Wenlu, Dong, Jibin, Wang, Jinxin
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 13.02.2020; Amer Chemical Soc
• Subjects: Chemistry, Medicinal; Life Sciences & Biomedicine; Pharmacology & Pharmacy; Science & Technology; SYSTEM; DEPRESSION; CELLS; ALPHA; MECHANISMS; HIPPOCAMPAL NEUROGENESIS; DERIVATIVES
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.9b00739

Recent studies on sphingolipids suggest that acid sphingomyelinase (ASM), which plays a central role in the pathogenesis of major depression, is emerging to be a novel target for developing antidepressants. Herein we first described the design, synthesis, and biological evaluation of hydroxamic acid-based direct inhibitors of ASM with the effort of validating their antidepressant effects in vivo. As a result, a series of novel ASM inhibitors were developed using a structure-based approach. Our studies demonstrated that the administration of 21b improved depression-like behaviors of rats. Importantly, this positive result was relevant to the inhibition of ASM and the increasing neurogenesis in hippocampus. To the best of our knowledge, this is the first time that direct inhibitors of ASM were developed to support the possibility of ASM as a potential therapeutic target for depression.